Results 51 to 60 of about 6,630,927 (326)

Cross-protection by Pseudomonas aeruginosa polysaccharides [PDF]

open access: yesInfection and Immunity, 1982
High-molecular-weight polysaccharide from Pseudomonas aeruginosa immunotypes 1 and 2 gave cross-protection in outbred CD-1 mice challenged with the heterologous immunotype organism. Both active immunization with 50 micrograms of polysaccharide, as well as passive transfer of immune serum were effective.
openaire   +2 more sources

Sequence-based prediction for vaccine strain selection and identification of antigenic variability in foot-and-mouth disease virus [PDF]

open access: yes, 2010
Identifying when past exposure to an infectious disease will protect against newly emerging strains is central to understanding the spread and the severity of epidemics, but the prediction of viral cross-protection remains an important unsolved problem ...
A Bastos   +58 more
core   +4 more sources

Cross-Protection of Hepatitis B Vaccination among Different Genotypes

open access: yesVaccines, 2020
Hepatitis B (HB) vaccination is the most effective method for preventing HB virus (HBV) infection. Universal HB vaccination containing recombinant HB surface antigens (HBsAg) is recommended.
Takako Inoue, Yasuhito Tanaka
semanticscholar   +1 more source

MiRNA Targeted NP Genome of Live Attenuated Influenza Vaccines Provide Cross-Protection against a Lethal Influenza Virus Infection

open access: yesVaccines, 2020
The miRNA-based strategy has been used to develop live attenuated influenza vaccines. In this study, the nucleoprotein (NP) genome segment of the influenza virus was inserted by different perfect miRNA-192-5p target sites, and the virus was rescued by ...
Feixia Gao   +8 more
doaj   +1 more source

Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs [PDF]

open access: yes, 2012
Hepatitis E virus (HEV), the causative agent of hepatitis E, is primarily transmitted via the fecal-oral route through contaminated water supplies, although many sporadic cases of hepatitis E are transmitted zoonotically via direct contact with infected ...
Córdoba, Laura   +5 more
core   +1 more source

BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design

open access: yesFrontiers in Immunology, 2019
The Bacillus Calmette-Guérin (BCG) is a live attenuated tuberculosis vaccine that has the ability to induce non-specific cross-protection against pathogens that might be unrelated to the target disease.
Camila Covián   +9 more
semanticscholar   +1 more source

Live Attenuated African Swine Fever Viruses as Ideal Tools to Dissect the Mechanisms Involved in Cross-Protection

open access: yesViruses, 2020
African swine fever (ASF) has become the major threat for the global swine industry. Furthermore, the epidemiological situation of African swine fever virus (ASFV) in some endemic regions of Sub-Saharan Africa is worse than ever, with multiple virus ...
E. López   +11 more
semanticscholar   +1 more source

Developing an understanding of cross-protection by Citrus tristeza virus

open access: yesFrontiers in Microbiology, 2013
Citrus tristeza virus (CTV) causes two citrus diseases that have caused devastating losses in global citrus production. The first disease is quick decline of trees propagated on the sour orange rootstock.
Svetlana Y Folimonova
doaj   +1 more source

Memory Th17 cell-mediated protection against lethal secondary pneumococcal pneumonia following influenza infection

open access: yesmBio, 2023
Streptococcus pneumoniae (Sp) frequently causes secondary pneumonia after influenza A virus (IAV) infection, leading to high morbidity and mortality worldwide. Concomitant pneumococcal and influenza vaccination improves protection against coinfection but
Yong Li   +10 more
doaj   +1 more source

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. [PDF]

open access: yes, 2015
OBJECTIVE: To investigate the incremental cost effectiveness of two dose human papillomavirus vaccination and of additionally giving a third dose. DESIGN: Cost effectiveness study based on a transmission dynamic model of human papillomavirus vaccination.
Brisson, Marc   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy